CDK4/6 overexpression and CCND1 amplification are frequently detected in HR+ BC [9, 11]; in addition, Rb inactivation, E2F1 overexpression and the persistent cyclin D1 expression are frequently associated with the development of endocrine resistance in HR+ BC [12]. This evidence concerns the gene E2F1 and breast cancer.